Abstract
Above-the-knee femoro-popliteal bypass (ATKFPB) is a standard surgical intervention for peripheral arterial occlusive disease. While both autogenous vein and synthetic polytetrafluoroethylene (PTFE) grafts are commonly used, their long-term comparative efficacy has remained a subject of clinical debate. This study demonstrates that autogenous vein grafts provide significantly better long-term patency and limb salvage rates compared to PTFE grafts over a 10-year follow-up period.
Introduction
Peripheral arterial occlusive disease (PAOD) can lead to debilitating symptoms ranging from claudication to limb-threatening ischemia. When endovascular options are not suitable, above-the-knee femoro-popliteal bypass (ATKFPB) is performed to restore blood flow. Historically, the autogenous great saphenous vein (GSV) has been the "gold standard" conduit. However, synthetic PTFE grafts are often utilized to reduce operative time or preserve the GSV for potential future coronary artery bypass grafting. This study investigates whether the short-term equivalence often cited for these materials holds true over a decade of follow-up.
Methods
Researchers at Samsung Medical Center conducted a retrospective review of 253 ATKFPB procedures performed between 2003 and 2014. The cohort included 107 autogenous vein grafts and 146 PTFE grafts. Patients were monitored postoperatively using duplex ultrasonography or CT angiography. The primary endpoints were primary, primary-assisted, and secondary patency rates, as well as limb salvage rates, analyzed using Kaplan-Meier methods over a 120-month horizon.
Key Results
The study revealed a significant divergence in long-term outcomes between the two graft types. While primary patency did not show a statistically significant difference (75% for vein vs. 42% for PTFE at 10 years, $P = 0.330$), the "assisted" and "secondary" metrics demonstrated a clear advantage for autogenous conduits.
As shown in the patency curves, vein grafts demonstrated vastly superior primary-assisted patency (88% vs. 42%, $P = 0.003$) and secondary patency (91% vs. 49%, $P = 0.013$). Crucially, the limb salvage rate was significantly higher in the vein group.
No patients in the vein group required major amputation due to graft failure, whereas 4.8% of the PTFE group suffered limb loss ($P = 0.019$). Graft occlusion was nearly four times more common in the PTFE group (20.5% vs. 5.6%).
Discussion: The "Mode of Failure" Advantage
The most critical insight from this long-term data is the difference in how these grafts fail. PTFE grafts often fail via sudden thrombosis, leading to acute limb ischemia in 53.3% of cases. In contrast, vein grafts typically fail due to gradual intimal hyperplasia, which manifests as a return of mild claudication. This slower progression provides a "window of opportunity" for surgeons to intervene and perform revisions, explaining the high primary-assisted patency rates for veins.
Furthermore, the traditional argument for "saving the vein" for heart surgery is becoming less compelling as endovascular treatments for coronary disease advance and alternative conduits become more common. The authors argue that the long-term limb-saving benefits of using the vein for ATKFPB outweigh the theoretical need to preserve it for future CABG.
Conclusion
For above-the-knee femoro-popliteal bypass, autogenous vein grafts should be prioritized whenever possible. Their superior durability, ease of rescue, and significantly lower risk of catastrophic limb-threatening failure make them the clear choice for long-term success. Rigorous postoperative surveillance is essential to identify and treat vein graft narrowing before total occlusion occurs, maximizing the "assisted" patency advantage.
Summary updated